2 Tower Place, Suite 940
South San Francisco
About Verge Genomics
Currently, it takes 12 years and $2.6 billion to get a single drug to market, with the drug discovery and development process costing $1.4 billion. At Verge Genomics, we believe there is a better way: we aim to improve the traditional drug discovery process with approaches based on systems biology, machine learning on human patient data, and drug screening in human cell cultures.
Founded in 2015 by CEO Alice Zhang, we’ve raised $32 million in Series A financing to build a next-generation biopharmaceutical company focused on accelerating development of life-saving treatments for patients with neurodegenerative diseases, including ALS, Parkinson’s Disease, and Alzheimer’s Disease.
As an emerging startup, Verge Genomics provides growth opportunities into other areas of the company. Being one of the early employees at Verge, your work will have a direct impact on the foundation of a groundbreaking new drug development model. You will be empowered to own your work and makes real decisions. In addition to competitive compensation and benefits, we offer perks like unlimited vacation/sick days, and free lunch delivered every day.
+ Patient Driven - Inspired and driven by the people who need us
+ Team of Founders - We are each responsible for the success of the company and each other
+ Transparency - Express ourselves with candor
+ Growth Mindset - Always seeking opportunities to improve
+ Grit - Persevere in the face of adversity
Alice Zhang Is Using AI To Transform Drug Discovery - 30 Under 30 - Forbes. Alice Zhang’s startup, Verge Genomics, thinks merging the latest in computer science with new technologies for decoding the human genome can improve the success rate for new drug discovery. Verge is focused on Alzheimer’s and Parkinson’s, areas that most drug companies have abandoned as hopeless.
1 article with Verge Genomics
Verge Genomics, a drug discovery company that uses artificial intelligence and machine learning to develop new therapeutics, secured $32 million in a Series A financing round to accelerate its drug discovery programs.